Recently, we developed a novel PAD4 inhibitor, ZD-E-1M, which was based on YW3-56 with the Nα-amide-dimethylnaphthylamine moiety replaced with nitro-benzofurazan, which inhibited PAD4 enzyme activity when applied in the low-micromolar range in vitro and showed potent antitumor and antimetastatic activities in a 4T1 breast cancer model by inhibiting H3 citrullination and NET formation [301]. This evidence concerns the gene PADI4 and breast cancer.